New research shows that dapagliflozin has significant benefits in treating chronic kidney disease (CKD) in patients with severe stages of the disease. The drug, when combined with integrated CKD care, improved outcomes compared to CKD care alone. The DAPA advKD trial included patients with an eGFR less than 20 mL/min/1.73 m2, which is a first for SGLT2 inhibitor renal outcome trials. Safety findings showed no significant differences in major adverse cardiovascular events or electrolyte imbalances. This study fills an evidence gap in using SGLT2 inhibitors for patient with advanced CKD and shows potential for preserving renal function and delaying the need for renal replacement therapy.
Source link
Dapagliflozin Safe and Effective in CKD Stages 4 and 5
